Difference between revisions of "Veterinary medicine"
(stub) |
(ownership) |
||
| Line 3: | Line 3: | ||
|constitutes=medical concept,Big Pharma | |constitutes=medical concept,Big Pharma | ||
|description=The branch of medicine that deals with the prevention, control, diagnosis, and treatment of disease, disorder, and injury in animals. | |description=The branch of medicine that deals with the prevention, control, diagnosis, and treatment of disease, disorder, and injury in animals. | ||
| − | |start | + | |start= |
}} | }} | ||
'''Veterinary medicine''' is the branch of [[medicine]] that deals with the prevention, control, [[diagnosis]], and treatment of disease, disorder, and injury in [[animals]]. Along with this, it deals with animal rearing, husbandry, breeding, research on [[nutrition]], and product development. The scope of veterinary medicine is wide, covering all animal species, both domesticated and wild, with a wide range of conditions that can affect different species. | '''Veterinary medicine''' is the branch of [[medicine]] that deals with the prevention, control, [[diagnosis]], and treatment of disease, disorder, and injury in [[animals]]. Along with this, it deals with animal rearing, husbandry, breeding, research on [[nutrition]], and product development. The scope of veterinary medicine is wide, covering all animal species, both domesticated and wild, with a wide range of conditions that can affect different species. | ||
| − | The global veterinary medicine market size was estimated at USD 29.4 billion in [[2021]] and is expected to grow at a compound annual growth rate (CAGR) of 7.3% from [[2022]] to [[2030]].<ref>https://www.grandviewresearch.com/industry-analysis/veterinary-medicine-market</ref> | + | ==A Cash Cow for Big Pharma== |
| + | [[image:Animal Health market.png|thumb|500px]] | ||
| + | The global veterinary medicine market size was estimated at USD 29.4 billion in [[2021]] and is expected to grow at a compound annual growth rate (CAGR) of 7.3% from [[2022]] to [[2030]].<ref>https://www.grandviewresearch.com/industry-analysis/veterinary-medicine-market</ref> Six [[Big Pharma]] corporations - [[Pfizer]],[[Merck]],[[Sanofi]],[[Bayer]], [[Eli Lily]] and [[Novartis]] - control around 64% of the global animal health market. For them, animal health is a better and steadier source of revenue. Animal drugs take far less time, and cost far less, to develop and get to market. The approval for new animal drugs is far easier, as opposed to getting drugs approved for people. Firms also face much less pricing pressure.<ref>https://www.morningstar.com/articles/391588/pfizers-animal-health-unit-is-best-in-show</ref> | ||
| + | |||
| + | |||
{{SMWDocs}} | {{SMWDocs}} | ||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
| − | |||
Revision as of 20:16, 23 June 2022
 Veterinary medicine  (medical concept, Big Pharma)   | |
|---|---|
| The branch of medicine that deals with the prevention, control, diagnosis, and treatment of disease, disorder, and injury in animals. |
Veterinary medicine is the branch of medicine that deals with the prevention, control, diagnosis, and treatment of disease, disorder, and injury in animals. Along with this, it deals with animal rearing, husbandry, breeding, research on nutrition, and product development. The scope of veterinary medicine is wide, covering all animal species, both domesticated and wild, with a wide range of conditions that can affect different species.
A Cash Cow for Big Pharma
The global veterinary medicine market size was estimated at USD 29.4 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 7.3% from 2022 to 2030.[1] Six Big Pharma corporations - Pfizer,Merck,Sanofi,Bayer, Eli Lily and Novartis - control around 64% of the global animal health market. For them, animal health is a better and steadier source of revenue. Animal drugs take far less time, and cost far less, to develop and get to market. The approval for new animal drugs is far easier, as opposed to getting drugs approved for people. Firms also face much less pricing pressure.[2]
